GoodRx Holdings, Inc. provides information and tools that allow consumers to compare prices and save when buying prescription drugs in the United States. The company is headquartered in Santa Monica, California.
| Revenue (TTM) | $785.23M |
| Gross Profit (TTM) | $713.19M |
| EBITDA | $108.78M |
| Operating Margin | 11.80% |
| Return on Equity | 2.52% |
| Return on Assets | 3.05% |
| Revenue/Share (TTM) | $2.29 |
| Book Value | $1.84 |
| Price-to-Book | 1.97 |
| Price-to-Sales (TTM) | 1.62 |
| EV/Revenue | 1.934 |
| EV/EBITDA | 8.89 |
| Quarterly Earnings Growth (YoY) | -44.50% |
| Quarterly Revenue Growth (YoY) | -1.30% |
| Shares Outstanding | $107.18M |
| Float | $94.02M |
| % Insiders | 12.65% |
| % Institutions | 55.95% |
Volatility is currently expanding
GoodRx has rebounded from $2.50 per share, showing renewed growth momentum and improved consumer traction. New offerings have contributed to GDRX's recent positive developments, but the stock's rapid appreciation reflects these improvements. I remain marginally more positive, yet GDRX still presents considerable risk, warranting a continued neutral rating.
GoodRx CEO Wendy Barnes discusses the company's partnership with TrumpRx and efforts to lower prescription drug costs on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #clamancountdown #goodrx #trumprx #wendybarnes #prescriptiondrugs #drugprices #healthcare #health #medicine #pharmacy #patients #consumer #trump #donaldtrump #donald_trump
GoodRx NASDAQ: GDRX reported second-quarter 2026 revenue of $200.4 million and adjusted EBITDA of $63.7 million, representing a 31.8% adjusted EBITDA margin, as growth in its Pharma Direct and subscription businesses offset pressure in prescription transaction revenue.
The latest earnings from Oscar Health and GoodRx show both companies dealing with a changing customer base. The former company reported half-year earnings Thursday (Aug. 6) showing record profitability for the first six months of 2026, with revenues surging 70% to $4.9 billion.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2026. Second Quarter 2026 Highlights Revenue of $200.4 million Net income of $8.5 million; Net income margin of 4.3% Adjusted Net Income1 of $26.8 million; Adjusted Net Income Margin1 of 13.4% Adjusted EBITDA1 of $63.7 million; Adjusted EBITDA Margin1 of 3.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 5, 2026. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 6, 2026 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's bus.
GoodRx (GDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Investors interested in Medical Services stocks are likely familiar with GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks offers value investors a better bang for their buck right now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today launched GoodRx Companion, a new $14.99-per-month subscription that brings together free and low-cost generic medications, affordable online care visits, and savings on additional healthcare services in one simple program. Built for a healthcare environment where consumers are increasingly shouldering more out-of-pocket costs, even when they have insurance, Companion tu.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GDRX and any ticker you trade — then tracks every position and per-strategy win rate.
